Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
NCT00648284 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1100
Last updated 2008-10-15
Summary
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
Conditions
- Type 2 Diabetes Mellitus
- CV Risk
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials, MD · GlaxoSmithKline
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-03-31
More Related Trials
-
Rosiglitazone to Reverse Metabolic Defects in Diabetes
NCT00094796 ·Status: COMPLETED ·Phase: PHASE2
-
Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial
NCT00700856 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
NCT01455896 ·Status: COMPLETED ·Phase: PHASE3
-
Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina
NCT00225342 ·Status: WITHDRAWN ·Phase: PHASE4
-
Preferred Treatment of Type 1.5 Diabetes
NCT00194896 ·Status: COMPLETED ·Phase: NA
-
Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care
NCT01010100 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
NCT00419484 ·Status: COMPLETED
-
Role of Rosiglitazone on Pre-Diabetes Mellitus and Coronary Artery Disease
NCT01574820 ·Status: COMPLETED ·Phase: PHASE3
-
Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And/Or Type 2 Diabetes
NCT00306644 ·Status: COMPLETED ·Phase: PHASE4
-
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
NCT00329225 ·Status: COMPLETED ·Phase: PHASE4
-
SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
NCT05408936 ·Status: ACTIVE_NOT_RECRUITING
-
Effect of Thiazolidinedione Treatment Vascular Risk Markers
NCT00571506 ·Status: COMPLETED ·Phase: PHASE4
-
Rosiglitazone on Microalbuminuria in Type 2 Diabetics
NCT00500955 ·Status: COMPLETED ·Phase: PHASE3
-
Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease
NCT00513630 ·Status: COMPLETED ·Phase: PHASE4
-
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
NCT00367055 ·Status: COMPLETED ·Phase: PHASE4
-
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
NCT00379769 ·Status: COMPLETED ·Phase: PHASE3
-
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk
NCT05214573 ·Status: COMPLETED
-
Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy
NCT00515632 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease
NCT00479986 ·Status: COMPLETED ·Phase: PHASE4
-
Bexagliflozin Efficacy and Safety Trial
NCT02558296 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics
NCT00067951 ·Status: COMPLETED ·Phase: PHASE3
-
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
NCT07254572 ·Status: RECRUITING ·Phase: PHASE4
-
GW823093C For The Treatment Of Type 2 Diabetes Mellitus
NCT00370942 ·Status: TERMINATED ·Phase: PHASE2
-
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
NCT00318656 ·Status: COMPLETED ·Phase: PHASE4
-
Markers and Mechanisms of Vascular Disease in Type II Diabetes
NCT00256646 ·Status: COMPLETED